Related Experiment Video
Updated: Mar 17, 2026
09:46
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
20.6K
Thrombocytopenia-Platelet Support or Growth Factors?
R Manley1, M F Murphy1,2
1a Department of Haematology , The John Radcliffe Hospital , Oxford , UK.
Hematology (Amsterdam, Netherlands)
|July 16, 2016
Summary
Preventing and treating hemorrhage in patients with severe thrombocytopenia is crucial. Platelet transfusions remain essential, but hemopoietic growth factors and platelet substitutes offer promising alternatives to reduce demand.
Area of Science:
- Hematology
- Oncology Supportive Care
Background:
- Hemorrhage in severe thrombocytopenia is a significant complication of chemotherapy and radiotherapy.
- Platelet transfusions have been the standard treatment for over 30 years.
Purpose of the Study:
- To review current and emerging strategies for managing hemorrhage in thrombocytopenic patients.
- To discuss alternatives to platelet transfusions, including hemopoietic growth factors and platelet substitutes.
Main Methods:
- Literature review of platelet transfusion efficacy and safety.
- Exploration of novel therapeutic agents like thrombopoietin and platelet substitutes.
- Analysis of the potential impact of new therapies on platelet concentrate demand.
Main Results:
- Platelet transfusions are effective but have limitations and safety concerns.
- Hemopoietic growth factors (e.g., thrombopoietin) show promise for enhancing platelet recovery.
- Platelet substitutes are under development as potential alternatives.
Conclusions:
- While platelet transfusions remain vital, hemopoietic growth factors and platelet substitutes may reduce reliance on platelet concentrates.
- Further research is needed to establish the safety and optimal use of novel therapies.
- Platelet transfusions will likely be necessary for the foreseeable future.
Related Concept Videos
01:28Role of Hematopoietic Growth Factors
4.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
4.3K
01:18Structure and Function of Platelets
4.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.5K
01:22Formation of the Platelet Plug
10.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:01Regulation of Hematopoietic Stem Cells
4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K